Management of thrombocytopenia with ENHERTU1,2

Thrombocytopenia can occur in patients treated with ENHERTU.

  • Of the 371 patients with unresectable or metastatic HER2-low breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast04, the incidence of platelet count decrease was:
    • Grade 1 incidence 8.9%; Grade 2 incidence 5.4%; Grade 3 incidence 4.3%; Grade 4 incidence 1.1%; Grade 5 incidence 0%
  • Based on the severity of thrombocytopenia, manage through treatment interruption or dose reduction

Dose modifications for thrombocytopenia1

Severity Treatment modification
Grade 3
(platelets less than 50 to 25 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose
Grade 4
(platelets less than 25 x 109/L)

Toxicity grades are in accordance with NCI-CTCAE v.5.0.

Review management information for these other potential treatment risks:

Get ENHERTU Resources for You and Your Practice

An ENHERTU resource guide summarizing the efficacy and safety, dosing and administration, and recommendations for managing adverse reactions
Ready to learn more about ENHERTU?
HER2, human epidermal growth factor receptor 2; NCI-CTCAE, National Cancer Institute-Common Terminology Criteria for Adverse Events.